What consequence can a biotechnology company face for failing to adhere to EPA regulations?

A biotechnology company that fails to adhere to EPA regulations can face serious consequences, including significant fines or even a shutdown of operations. The Environmental Protection Agency (EPA) enforces regulations designed to protect human health and the environment, and non-compliance can lead to legal actions. Fines serve to penalize companies for their failures, deter future violations, and ensure accountability. In severe cases, continued non-compliance or egregious violations could result in the suspension or revocation of a company's operating licenses, forcing them to cease operations until compliance is achieved.

This situation stands in stark contrast to the other choices. A failure to comply with regulations is unlikely to result in an increase in market share, as lack of adherence could damage a company's reputation and customer trust. Similarly, companies that do not follow EPA guidelines are unlikely to receive grants for further research. Grants are usually awarded to entities demonstrating responsible research practices and compliance with regulatory frameworks. Positive media coverage would also be unlikely, as news related to regulations typically focuses on negative aspects, such as penalties or company failures, rather than celebrating a company's non-compliance.